Bioxcel Therapeutics shares up 10.47% intraday after disclosing AI platform and pipeline in quarterly report.

Bioxcel Therapeutics surged 10.47% intraday, as the company disclosed in its Form 10-Q report on November 12, 2025, that it is an AI-driven biopharmaceutical firm developing transformative drugs in neuroscience and immuno-oncology. Its AI platform aims to reduce R&D costs and accelerate development, with key products including approved IGALMI for acute agitation in schizophrenia or bipolar disorder, BXCL501 for opioid withdrawal, and BXCL701 for immuno-oncology.